Pharmaceutical World Sales Increase to Over $880 Billion Per Year Including Large Sales Increases in the "Pharmering Countries" by International Pharmaceutical Supply Chain Fraud Whistleblower Lawyer and International Adulterated Drug Whistleblower Lawyer Jason S. Coomer

Pharmaceutical World Sales Increase to Over $880 Billion Per Year Including Large Sales Increases in the "Pharmering Countries" by International Pharmaceutical Supply Chain Fraud Whistleblower Lawyer and International Adulterated Drug Whistleblower Lawyer Jason S. Coomer

Every year over $4.1 trillion (US dollars) is spent worldwide on health services including approximately $850 billion (US dollars) that is spent in the pharmaceutical market on drugs and medications.  In 2011, it is estimated that global pharmaceutical sales are expected to grow by 5% to 7% to around $880 billion.  This growth in sales is led by the 17 so-called "pharmerging countries," which include China, Brazil, Russia, India, Venezuela, Poland and the Ukraine.  These "pharmerging countries", are forecast to see their pharmaceutical spending grow at a 15% to 17% rate in 2011, to between $170 billion and $180 billion overall.

Eight pharmerging countries are amongst the top 20 world pharmaceutical markets, and China is one of the “top three” or will be in the near future.  A few high-profile pharmaceutical companies have been successful in gaining a foothold in these pharmering countries.  These footholds include Abbott’s acquisition of Piramal Healthcare in India — a deal that could potentially make the US giant the top player in this country.  Bayer's and Novartis' investments in China including Novartis'  commitment to invest $1 billion USD in R&D in China and its $125 million USD investment to buy 85 percent stake in a privately held vaccine company.  Pfizer has made inroads into the Russian health care system with a discount-card system in Russia  Sanofi Aventis has purchased Medley, Brazil’s third-largest pharmaceutical company.  GSK and Lilly have also announced anticipated doubling their revenue in emerging markets by 2015.

It is estimated that approximately 10 to 25% of public health care procurement spending including drug contracts, medicines, pharmaceuticals, medical equipment, and medical devices is lost to corrupt and fraudulent acts including adulterated drugs.  As such, there is an international movement to reward pharmaceutical professionals and health care professionals that expose fraudulent and corrupt practices that cost hundreds of billions of dollars and cost lives.  This international movement includes SEC Foreign Corrupt Practices Act Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.   

Increased Competition and Expansion in the Pharmaceutical Industry Creates Opportunity for Increased Corruption in Pharmaceutical Procement  and Expands the Opportunity for Fraud in Pharmaceutical Drug Supply Chains that can create Dangerous Adulterated Drugs

Included in this globalization of the pharmaceutical industry is a shift in many international pharmaceutical manufacturing supply chains where raw material supplies for pharmaceuticals, medical supplies, and medical equipment that were traditionally from the United States and Europe are now produced in from China and India as well as other emerging countries.  This manufacturing shift create has created an environment where adulterated ingredients to pharmaceuticals, medical supplies, and medical devices may be used in the manufacturing of these products and can create dangerous and defective drugs, medical supplies, and medical devices being purchased by governments and given to patients. 

International Pharmaceutical Supply Chains Include Active Pharmaceutical Ingredient (API) Manufacturers, Pharmaceutical Intermediate Manufacturers, and Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs

Pharmaceutical suppliers of raw materials to the pharmaceutical industry include suppliers of active pharmaceutical ingredients (APIs), intermediates, and excipients.   It is the United States Food and Drug Administration's expectation that current good manufacturing practices (CGMP) be used for the manufacturing, processing, packing, or holding (i.e., storage) of active pharmaceutical ingredients (APIs), intermediates, and excipients.  Further, the FDA recommends that laboratory controls should include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures to ensure that raw materials, intermediates, APIs, and containers conform to established standards of quality and purity.

International Adulterated Drug Supply Chain Whistleblower Reward Lawyer, International Pharmaceutical Supply Chain Fraud Whistleblower Lawyer, Medicine Supply Chain Whistleblower Reward Lawyer, Medicine Supply Chain Fraud Lawyer, and Pharmaceutical Supply Chain Foreign Corrupt Practices Act Lawyer

International Whistleblowers along the pharmaceutical supply chain and other health care professionals are being offered large potential rewards to blow the whistle on adulterated pharmaceutical ingredients, adulterated medicine, adulterated drugs, contaminated medical supplies, and defective medical devices.  These whistleblower rewards can come from SEC Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.  For more information on these potential whistleblower rewards, feel free to go to the following web pages: International Adulterated Drug Supply Chain Whistleblower Reward Lawsuits, Drug Safety Fraud Qui Tam Adulterated Drug Whistleblower Reward Lawsuits, Off-Label Pharmaceutical Medicare Fraud Whistleblower Lawsuits and Drug Procurement Illegal Kickback Lawsuit

Austin Sees Increase in Fatal Pedestrian Automobile Accidents

The Texas Driver's Handbook is very clear that pedestrian's have the right of way on Texas roads.  It warns drivers to avoid turning their vehicles into a deadly weapon and to always be aware of any pedestrians.  This rule is especially true when a pedestrian is in a crosswalk or in a schooling crossing.  In these situations, pedestrians always have the right of way.

Increased number of auto-pedestrian fatalities in Austin arouses concern

Austin Texas Pedestrian Accident Lawsuit Information

What GCs Should Know About the Achilles Heel of Anti-Bribery Law

What GCs Should Know About the Achilles Heel of Anti-Bribery Law

International Whistleblowers Are Receiving Large Rewards for Exposing Government Procurement Bribe Schemes and other Government Corruption by International Government Procurement Bribe Whistleblower Lawyer, International Procurement Contract Bribe Lawyer, and International Procurement Illegal Kickback Whistleblower Attorney Jason S. Coomer

Worldwide government purchasing or government procurement is estimated to be over $10 Trillion each year.  Of this large amount of government purchasing, it is estimated that as much as 20% may be through illegal bribes, kickbacks, and other illicit payments.  Government procurement spending includes military spending; public works projects; public health care (pharmaceuticals, medical equipment, & hospitals); ports, transportation, & roads; mining and oil extraction; power grid and stations; education; law enforcement; and sanitation services.  Because of the vast amount of money spent by governments on government procurement, there are many different types of government procurement illegal bribery schemes, illegal kickback schemes, and other illicit payment schemes that have been created to steal money from the public at the expense of a country's citizens.

For more information on Exposing Government Corruption and Illegal Government Purchasing Kickbacks, please feel free to go to the following web page on International Whistleblower Government Procurement Reward Bounty Actions.

International Medicine Procurement Illegal Bribe Whistleblower Reward Lawsuit, Medicines Supply Chain Bribe Whistleblower Lawsuit, and International Medicine Procurement Foreign Corrupt Practices Act Lawsuit Information by International Medicine Procurement Illegal Bribe Whistleblower Lawyer, Drug Procurement Contract Bribe Lawyer, and International Medicines Illegal Kickback Whistleblower Reward Lawyer Jason S. Coomer

International Medicine Procurement Illegal Bribe Whistleblower Reward Lawsuit, Medicine Supply Chain Bribe Whistleblower Lawsuit, Drug Procurement Illegal Kickback Lawsuit, Pharmaceutical Representative Whistleblower Reward Lawsuit, and Drug Representative Foreign Corrupt Practices Act Lawsuit Information by International Medicine Procurement Illegal Bribe Whistleblower Lawyer, Drug Procurement Contract Bribe Lawyer, and International Drug Representative Illegal Kickback Whistleblower Reward Lawyer Jason S. Coomer

 

Every year over $4.1 trillion (US dollars) is spent worldwide on health services including approximately $750 billion (US dollars) that is spent in the pharmaceutical market on drugs and medications. It is estimated that approximately 10 to 25% of public health care procurement spending including drug contracts, medicines, pharmaceuticals, medical equipment, and medical devices is lost to corrupt and fraudulent acts.  These acts include government official bribes, illegal kickbacks, and other illicit payment and fraud schemes.

The World Health Organization (WHO) defines the term "medicines chain" to be the steps that are required for the creation, regulation, management and consumption of pharmaceuticals.  In other words it is the medication supply chain in the pharmaceutical industry from creation to end user. According to the World Health Organization, corruption is common in the international pharmaceutical sector and occurs throughout all stages of the medicines supply chain, from research and development to dispensing and promotion.  These unethical and corrupt practices in the medicines supply chain can take many forms such as falsification of evidence, false certification of adulterated drugs, import false certifications, export false certifications, conflicts of interest, and illegal bribe and kickback schemes. 

As such, the World Health Organization and many other international public health organizations are seeking public policy changes under the umbrella of good governance initiatives within the medicines chain to reduce government corruption and optimize public health outcomes.  Some proposed public policy changes that can help reduce corruption and fraud in the pharmaceutical medicines chain include: 1) protection of international medicines supply chain whistleblowers; 2) offering financial incentives to international medicines chain whistleblowers; 3) passage of legislation and regulation for drug quality control and official certifications to monitor the transport of medications including the export and import of medicines throughout world and along international medicines supply chains; 4) increased enforcement mechanisms for violations of existing pharmaceutical laws and regulations; and 5) increased resources for conflict of interest management and checks to ensure key people in the medicines chain are not accepting illegal bribes, kickbacks, and other illicit payments.

In response to these good governance initiatives, the international community including the United States, United Kingdom, and many other countries have enacted new anti-bribery and anti corruption laws that will enable persons with knowledge of international medicines supply chain fraud and corruption to expose the illegal acts and reap rewards from blowing the whistle, while being protected from potential retaliation from the wrong doers.

While there are an increasing number of reported cases of corruption in the medicines chain, much unethical practice has historically gone unreported.  This is changing as new whistleblower protections and whistleblower financial incentives are coming into place to help overcome  institutionalized corruption in the pharmaceutical medicines chain and to provide protection for courageous whistleblowers that want to change the institutionalized corruption that is damaging their countries.

Because medicines typically change hands several times in the medicines chain between the drug manufacturer and patients, the large number of steps in the medicines chain allows numerous opportunities for unethical practices to take place.  Therefore increased regulations and laws throughout the medicines chain including manufacturing quality assurances, export regulations and inspections, import regulations and inspections, health care provider regulations and inventory policies, and patient protections are needed.  Fortunately, the new international whistleblower laws will allow international whistleblowers with specialized knowledge of the corruption to blow the whistle on fraud, false certifications, and illicit payments that are occurring throughout the medicines chain.     

A lack of transparency and accountability within the medicines chain can also contribute to unethical practices and corruption.  Therefore increased enforcement mechanisms are needed for violations of existing pharmaceutical laws and regulations.  These enforcement mechanisms include "SEC Bounty Actions" that allow private citizens to work through international medicines supply chain whistleblower reward lawyers to expose significant fraud and obtain large bounties for successful prosecution of pharmaceutical illicit payment schemes.  Ideally, these international medicines supply chain whistleblower reward actions will track fraud and corruption to the root causes and help reform corporate corruption of public health care systems.  Through international pharmaceutical representative whistleblowers, international drug executive whistleblowers, foreign government official whistleblowers, health care provider whistleblowers, and other medicines supply chain whistleblowers, the international community can efficiently identify, expose, and remedy medicines chain corruption.

International Medicines Supply Chain Whistleblower Reward Lawyer, International Medicines Chain Drug Contract Bribe Whistleblower Lawyer, Medicine Contract Illegal Kickback Lawyer, Medicines Chain Whistleblower Reward Lawyer, Medicines Supply Chain Fraud Lawyer, and Medicines Supply Chain Foreign Corrupt Practices Act Lawyer

International whistleblowers can recover large amounts of money for exposing international medicine procurement kickbacks, medicines supply chain bribes, and other violations of the Foreign Corrupt Practices Act.  As such, pharmaceutical representatives, international drug executives, government officials, physicians, health care providers, community activists, and other persons, who are the original source of specialized knowledge of international drug company bribes, international pharmaceutical company illegal kickback schemes, public health medicine procurement bribery schemes, and other illicit payments for drug procurement, medical device procurement, medication, pharmaceutical, and medical equipment contracts.  

For more information on  Public Health Care Procurement Bribe Whistleblower Reward Lawsuits, please feel free to go to the following web page on International Medicine Supply Chain Whistleblower Reward Lawsuit, International Drug Representative Whistleblower Reward Lawsuit, Drug Contract Bribe Whistleblower Lawsuit, Medication Contract Illegal Kickback Lawsuit, Pharmaceutical Representative Whistleblower Reward Lawsuit, and Drug Representative Foreign Corrupt Practices Act Lawsuit Information. 

China Import Export Bribe Whistleblower Reward Lawsuit, China Customs Illegal Kickback Informant Reward Lawsuit, & China Illegal International Trade Bounty Action Information by China International Business Bribe Bounty Lawyer, China Import Export Bribe Lawyer, and China Foreign Corrupt Practices Act Violation Lawyer Jason S. Coomer

China Import Export Bribe Lawsuit, China Business Bribe Bounty Reward Lawsuit, China Customs Illegal Kickback Informant Reward Lawsuit, & China Illegal International Trade Bounty Action Information by China International Business Bribe Bounty Lawyer, China Import Export Bribe Lawyer, and China Foreign Corrupt Practices Act Violation Lawyer Jason S. Coomer

Foreign multinational corporations investing in the People's Republic of China and Chinese multinational corporations investing in other countries can often be held accountable when they violate the Foreign Corrupt Practices Act (FCPA) and other anti-bribery laws.  These laws prevent government corruption including illegal payments to customs agents, bribes for construction contracts, illegal kickbacks for regulatory approval, and other illegal business practices.  Through the Foreign Corrupt Practices Act (FCPA), whistleblowers are encouraged to step up and confidentially report corruption.  Under new whistleblower protections, these Chinese whistleblowers and multinational corporation whistleblowers can confidentially report violations through a Foreign Corrupt Practices Act Lawyer and receive large financial rewards for being the first to properly expose significant government corruption. 

 

China's Emerges as an Economic Superpower through International Trade, Modernizing Chinese Ports & Distribution Systems, Logistics Parks, and Allowing Foreign Investment

The People's Republic of China (PRC) has a population of over 1.3 billion and is the most populous state in the world.  The Communist Party of China governs the People's Republic of China and exercises control over 22 provinces (23 provinces if Taiwan is included), five autonomous regions, four directly controlled municipalities (Beijing, Tianjin, Shanghai, and Chongqing), and two mostly self-governing special administrative regions (SARs), Hong Kong and Macau. Because of this government control of Chinese industries, bribery of Chinese officials, Chinese government bribes, and illegal kickbacks to Chinese customs agents and Chinese regulatory agents are more common. 

The capital city of the People's Republic of China (PRC) is Beijing.  Since the introduction of market-based economic reforms in 1978, China has become the world's fastest-growing major economy.  Since the 1980s, the People's Republic of China has used international trade and foreign investment to emerge as an economic superpower.  From 2001 to 2010, China's international trade imports and exports increased from about $500 billion per year to approximately $3 trillion per year.  A large part of this rapid expansion can be attributed to foreign direct investment that has surged into China.  As of 2012, the People's Republic of China (PRC) has become the world's second-largest economy by both nominal GDP and purchasing power parity (PPP), and is also the world's largest exporter and second-largest importer of goods.

China has spent large amounts of money to construct and modernize approximately 160 Chinese ports including about 50 coastal ports and 110 inland river ports. These ports are an essential part of the development of China's massive import and export international trade.  By investing billions of dollars in these ports, China had been able to drastically increase the total handling capacity of harbors along China’s coast as well as continuously expand its import and export businesses. 

The Modernization of Chinese Ports & Distribution Systems by Allowing Foreign Investment has Greatly Expanded China's Ability to Import and Export Goods as well as Develop Manufacturing Industries

This Chinese import and export network is formed around three major harbor areas: 1) The Bohai Sea area of northern China (including Beijing) is serviced by the ports of Tianjin, Dalian and Yantai; 2) the Yangtze River Delta area includes the ports of Shanghai and Ningbo; and 3) the Pearl River Delta in southern China includes the ports of Shenzhen, Guangzhou and Hong Kong. These ports have experienced tremendous growth and expansion over the last decade and have helped China increase its international trade.

To help develop Chinese ports, the Chinese government has encouraged foreign direct investment into port modernization programs.  By bringing in foreign investments including resources and technology, the Chinese government has been able to successfully expand international trade including imports and exports.  Through liberalization of foreign investment restrictions in the modernization of Chinese ports, the Chinese ministries have been able to improve international trade and port logistics  including in the areas of transportation, freight forwarding, storage, warehousing, and port management.

China's largest and busiest ports include Port of Hong Kong, Port Shanghai, Port of Shenzhen, Port of Guangzhou, Port of Qingdao, Port of Dalian, Port of Lüshunkou, Port of Jiuzhou, Port of Suzhou, Port of Xiamen, Port of Ningbo, and Port of Tianjin.  This thriving network of Chinese ports have seen modernization and logistical technology used to greatly increase China's ability to import and export goods leading to economic prosperity.

However, with this expansion on imports and exports has come fierce competition for Chinese business and huge profits that can be obtained through government corruption and illegal bribes.  These violations include violations of the Foreign Corrupt Practices Act by Multinational Corporations, their wholly owned subsidiaries, joint venture partners, and agents.  These complicated business structures commonly create elaborate bribery schemes to obtain and retain Chinese business including bribing public officials and customs agents to circumvent container certification, legal customs, import requirements, and other legal requirements.  These illicit payments are often paid through an elaborate kickback scheme where employees and agents of large multinational corporation or their wholly owned subsidiary falsely characterize illicit payments to public officials as commissions or other expenses.  Many of these illicit payments are made through foreign banks and are actually kickbacks paid to government officials.

China Import Bribe Lawyer, China Export Bribe Lawyer, China FCPA Violation Lawyer, Chinese Government Official Illegal Payment Whistleblower Reward Lawyer, Chinese Government Corruption Confidential Whistleblower Lawyer, China Business Bribe Bounty Action, China Illegal Kickback Informant Reward Lawyer, China Illegal International Trade Bounty Action Lawyer, & Peoples' Republic of China Government Agent Illegal Payment Bounty Lawyer

There is a worldwide effort by the international community to crack down on government corruption, illegal kickbacks, and illegal bribes.  This effort includes initiatives by the United States to identify and prosecute illegal bribery schemes of government officials.  To identify hard to detect bribery schemes, the United States Securities Exchange Commission is offering large bounties (whistleblower rewards) for persons with specialized knowledge of systematic bribes and complicated bribery schemes.  These large economic incentives are designed to encourage import export experts, customs experts, logistics experts, and other persons aware of complicated import and export bribes and government fraud to step up and become a confidential import export bribe whistleblower, customs fraud whistleblower, logistics whistleblower, and other international trade whistleblower. 

The United States Bounty Actions are set up under the Foreign Corrupt Practices Act (FCPA).  The FCPA applies to “issuers” (U.S. and foreign companies listed on U.S. securities exchanges and their employees); “domestic concerns,” which run the gamut of business entities organized under U.S. laws or with their principal place of business in the United States; the officers, directors, employees, and agents of those U.S. business entities (irrespective of nationality); U.S. citizens; U.S. resident aliens; “any person,” including all foreign persons, who commit an act in furtherance of a foreign bribe while in the United States, and U.S. businesses and nationals acting abroad. A Company must require all of its affiliated companies and all of their employees to comply with the Foreign Corrupt Practices Act.

For information on specific Chinese Ports and more information on China Import Bribe Whistleblower Actions and China Export Bribe Whistleblower Actions, please go to the following web pages on China False Container Certification Bribe Lawyer, China Export Bribe Lawyer, China Port Official Bribe Lawyer, Chinese Government Official Illegal Payment Whistleblower Reward Lawyer, and China Customs Agent Bribe Lawyer Information and China International Business Bribe Bounty Lawyer, China Import Export Bribe Lawyer, and China Foreign Corrupt Practices Act Violation Lawyer Information.

Medicaid Fraud Whistleblower Recovery Lawsuits Recover Billions by Medicaid Drug Marketing Fraud Whistleblower Lawyer, Medicaid Price Fraud Whistleblower Lawyer, Drug Formulary Fraud Lawyer, & Medicaid Drug Kickback Whistleblower Lawyer

The Federal Government and Several States Including Texas Are Making Large Recoveries Through Medicaid Drug Marketing Fraud Whistleblower Lawsuits and Medicaid Drug Price Fraud Whistleblower Lawsuits by Medicaid Drug Marketing Fraud Whistleblower Lawyer, Medicaid Price Fraud Whistleblower Lawyer, Drug Formulary Fraud Lawyer, & Medicaid Drug Kickback Whistleblower Lawyer

In January 2012, the State of Texas and a Medicaid drug marketing fraud  whistleblower squared off against Johnson and Johnson, Inc. and several related companies in Travis County District Court.  In the case, the State of Texas alleged that the large drug company systematically targeted the Texas Medicaid System and fraudulently misrepresented their drug, Risperdal, with false and misleading marketing information.  Further, that the defendants intentionally targeted opinion leaders in the medical community with financial incentives and misleading information in an effort to have the drug placed into treatment guidelines, model state treatment programs, formularies, Texas Vendor Drug Programs, and the Texas Medicaid preferred drug lists.

Attorneys for the State of Texas and Medicaid Marketing Fraud Whistleblower argued that they had reviewed millions of documents and could prove that the large drug company intentionally pushed Risperdal as a safer alternative to the typical medications despite rulings from the Food and Drug Administration that these assertions were not supported by scientific research.  Further, that the defendants orchestrated a fraudulent marketing scheme to seed medical literature with misleading information and influence key medical decision makers to increase Risperdal in the Texas Medicaid Program as well as used this information to push their drug as the established treatment in state Medicaid programs throughout the United States as well as in the Federal Medicare program.

As a result of this Texas lawsuit, the drug maker, Johnson and Johnson, Inc., agreed to settle the Texas Medicaid fraud case for $158 million.  Johnson and Johnson, Inc. has also agreed to a settlement where the drug company will will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal.  Johnson and Johnson, Inc. has also been hit in Medicaid fraud cases in South Carolina and Louisiana and was ordered to pay more than $250 million each.

Medicaid Drug Marketing Fraud Whistleblower Lawyer, Medicaid Price Fraud Whistleblower Lawyer, Drug Formulary Fraud Lawyer, & Medicaid Drug Kickback Whistleblower Lawyer

In a recent Medicaid Drug Fraud Whistleblower lawsuit, the Texas Attorney General Office argued that Johnson and Johnson, Inc. fraudulently manipulated the Texas Medication Algorithm Project (TMAP) in order to establish their drug as the standard of care in the medical industry included getting the drug placed on Medicaid Preferred Drug Lists, Hospital Formularies, and other standards of care.  TMAP is a decision-tree medical algorithm that was designed as a basis for psychiatric management guidelines for doctors treating certain mental disorders within Texas' publicly-funded mental health care system, along with manuals relating to each of them.  By fraudulently manipulating the Texas Medication Algorithm Project, drug companies can push their drug as the established treatment and reap huge profits from state Medicaid programs, Medicare, and insurance policies.

These fraudulent Medicaid drug marketing schemes can be extremely hard to identify as the drug manufacturers typically have large and sophisticated marketing and research departments filled with public relations experts and backed by huge resources to use to push a drug.  Through these experts and sophisticated marketing techniques, the drug manufacturers are able to seed medical research, manipulate decision makers, hire experts to support their research, and target government health care programs.  These marketing schemes are designed to expand drug sales beyond FDA approved uses into off-label uses and to avoid scrutiny of independent research.  

Further, these drug company marketing departments have also devised Physician and Medical Professional Profiling schemes that they can use to determine what best motivates a particular physician opinion leader and use this information combined with advanced marketing techniques to manipulate the well placed physician without the medical doctor even realizing that they are being manipulated.  These techniques include understanding that some medical doctors are research oriented while others are politically motivated, financially motivated, career motivated, or relationally motivated.  By understanding a medical doctor's predispositions, interests, and motivations, a drug company marketing department or medical device marketing department can use or manipulate a well placed medical doctor based on their profiled information and push opinion leaders in targeted medical communities and states to use a specific drug or medical device. 

As such, physician Medicaid fraud whistleblowers, drug company Medicaid fraud whistleblowers, neurologist Medicaid fraud whistleblowers, health care administrator Medicaid fraud whistleblowers, pharmacist Medicaid whistleblowers, and other medical professional whistleblowers are needed to blow the whistle on Billions of dollars in Health Care Fraud.    

Drug Company Influence on Standards of Care and Hospital Formularies Through Marketing Fraud, Fraudulent Research, and Manipulation

Many health care professions have become aware of the strong influence that drug companies now have in determining community standards of care for medication use in patients.  These drug companies push drug samples into many hospitals and often use powerful forms of manipulation including biased research, influencing key medical doctors, and kickbacks to get their drugs placed on hospital formularies. 

Because of the immense power and influence of drug companies, it is becoming common to have drug marketing executives and representative to be able to influence what drugs whole communities.  In many situations the drug companies are more powerful than individual doctors that are forced to follow hospital formularies.  This drug company manipulation of the medical community can be extremely dangerous because it takes important medical decisions out of the hands of individual medical doctors and allows the drug companies to push potentially dangerous drugs for off-label drug uses and in inappropriate situations. 

The drug industry's main goal is to make a profit.  Each drug company is trying to sell as much of their drug as they can regardless of the potential danger to patients or if there are cheaper more effective alternatives available.  If the marketing executives and drug representatives can get their drug placed on a hospital formulary or make it the standard of care in a community, they are able to make lots of money.  Once this is accomplished there are economic incentives to keep expanding the use of the drug to keep expanding off-label uses. 

Recently several large drug companies have been caught fraudulently marketing drugs for off-label purposes.  These drug companies have had to pay Billions of dollars for Medicare Marketing Fraud Off-Label Lawsuits, Medicaid Marketing Fraud Off-Label Lawsuits, and other health care fraud lawsuits.   Despite these large fines, Drug Companies have continued this practice because they are making profits of Hundreds of Billions of Dollars.

Drug Price Medicaid Fraud Whistleblower Lawyer, Inflated Average Wholesale Price Medicaid Fraud Whistleblower Lawyer, Medicaid Fraudulent Drug Price Lawyer, Drug Price Kickback Whistleblower Lawyer, Pharmaceutical False Price Whistleblower Lawyer, and Pharmacy Medicaid Drug Price Fraud Lawyer

State Attorney General Offices are also targeting retail pharmacy chains that seek to manipulate drug prices to their advantage.  These drug price Medicaid fraud whistleblower lawsuits include pharmacy chains that fail to perform required a drug utilization review and attempt to defraud government health care programs.  Many of these State Attorney General Offices are working with drug price fraud whistleblower Ven-A-Care.  This pharmacy drug price fraud whistleblower has been working on drug fraud cases since 1994 and has held state and federal governments recover more than $2 billion and has won roughly $380 million for itself in the process. 

On February 1, 2011, a Travis County, Texas jury found that a global pharmaceutical manufacturer had misrepresented drug prices to the state's Medicaid program and said the drug company should pay the state and federal government $170.3 million.  These Drug Price Medicaid Fraud Lawsuits are becoming more common as evidence is coming to light that the $700 Billion a year drug industry includes some large drug companies that are defrauding Medicaid, Medicare, the VA, Tricare, and other governmental benefit programs out of vasts amounts of money.

Several governmental officials have made it clear that those who defraud the Medicaid program, Medicare, the VA, Tricare, CHIP and other government benefit programs will be held accountable for their actions.  Recent changes in the False Claims Act and other Qui Tam laws have created stronger protections and economic incentives for whistleblowers with knowledge of drug price fraud and other forms of Medicare Fraud and Medicaid Fraud.  As such, it is important for drug price fraud whistleblowers, pharmaceutical representative whistleblowers, medical device sales representative whistleblowers, drug marketing representative whistleblowers, and other drug executive whistleblowers to blow the whistle on drug fraud pricing schemes.

Medicaid Drug Marketing Fraud Whistleblower Lawyers, Medicaid Drug Formulary Fraud Whistleblower Lawyers, Targeted Medicaid Off Label Marketing Fraud Whistleblower Lawyers, Medicaid Formulary Drug Fraud Whistleblower Lawyers, & Medicaid Drug Illegal Kickback Marketing Fraud Whistleblower Lawyers

For more on this topic, please go to the following webpages: Pharmacy Drug Price Fraud Whistleblower Lawsuit, Pharmacy Inflated Average Wholesale Price Medicaid Fraud Whistleblower Lawsuit, Medicaid Fraudulent Drug Price Fraud Whistleblower Lawsuit, Pharmacy Drug Price Kickback Whistleblower Lawsuit, Pharmacy False Price Information Lawsuit, and Pharmacy Employee Whistleblower Lawsuit Information and Medicaid Drug Marketing Fraud Whistleblower Lawsuit, Medicaid Drug Price Fraud Whistleblower Lawsuit, Medicaid Drug Formulary Fraud Whistleblower Lawsuit, Targeted Medicaid Off Label Marketing Fraud Whistleblower Lawsuit, Medicaid Formulary Drug Fraud Whistleblower, & Medicaid Drug Illegal Kickback Marketing Fraud Whistleblower Lawsuit Information.

Whistleblower Reward Lawsuit Information by Medicaid Fraud Whistleblower Reward Lawyer, Medicare Fraud Whistleblower Reward Lawyer, and Bounty Action Reward Lawyer Jason Coomer

Medicaid Fraud Whistleblower Reward Lawsuit, Medicare Fraud Whistleblower Reward Lawsuit, Securities Fraud Whistleblower Reward Bounty Action Lawsuit, IRS Fraud Whistleblower Reward Lawsuit, Defense Contractor Fraud Whistleblower Reward Lawsuit, and other Whistleblower Reward Lawsuit Information by Medicaid Fraud Whistleblower Reward Lawyer, Medicare Fraud Whistleblower Reward Lawyer, and Bounty Action Reward Lawyer Jason Coomer

Whistleblower Reward Lawsuits are the most effective method for identifying and preventing large scale fraud against the government, in financial markets, and in large corporations.  New whistleblower reward laws have harnessed the power of economic incentives by offering large monetary rewards to whistleblowers that properly report significant fraud.  These whistleblower reward laws have also increased whistleblower protections to prevent and punish retaliation against whistleblowers. 

Qui Tam Actions and Bounty Actions Create Economic Incentives through  Whistleblower Recovery Law that are Extremely Effective in Exposing and Preventing Fraud Against the Government as well as other Unlawful Conduct

Offering large financial awards and economic incentives to persons with knowledge of crimes and criminals including offering whistleblower rewards and whistleblower bounties have been an extremely effective method of identifying unlawful conduct, crimes, and criminals.  When the government offers the economic reward to private citizens for exposing fraud against the government, such actions are called "qui tam actions".  In these actions, the plaintiff is suing on their own behalf as well for the government and taxpayers.

The qui tam provisions of the False Claims Act are based on the theory that one of the least expensive and most effective means of preventing frauds on taxpayers and the government is to make the perpetrators of government fraud liable to actions by private persons acting under the strong stimulus of economic benefit as well as patriotic duty, personal ill will, and/or strong personal ethics.

The strong public policy behind creating an financial reward for whistleblowers is that  the government would be significantly less likely to learn of the allegations of fraud, but for persons in certain positions with specialized knowledge of Medicare fraud, Medicaid fraud, defense contractor fraud, investment fraud, foreign business fraud, tax fraud, or significant fraud that has been committed. Congress has made it clear that creating these financial incentives is beneficial not only for the government, taxpayers, and the realtor, but is an efficient method of regulating government to prevent fraud and fraudulent schemes.

The central purpose of the qui tam whistleblower reward provisions of the False Claims Act as well as the IRS whistleblower reward, SEC whistleblower reward, and CFTC whistleblower reward bounty actions is to set up incentives to supplement government regulation and enforcement by encouraging whistleblowers with specialized knowledge of significant fraudulent schemes against the government and the public to blow the whistle on the fraudulent and criminal acts.

The more recent enactment of the financial fraud whistleblower reward laws are response to large scale fraud that almost collapsed the world financial markets.  These new bounty actions work under the same premise as extremely successful qui tam whisleblower reward laws.  By encouraging private citizens with specialized knowledge of financial fraud, the government is seeking to deter investment fraud, securities fraud, SEC violations, retirement fund fraud, corporate malfeasance, violations of the foreign corrupt practices act, and other forms of financial fraud by offering rewards or bounties to persons that properly expose this fraud.

Qui Tam Whistleblower Reward Lawsuits and Whistleblower Reward Lawsuits from Medicare Whistleblower Reward Lawyer, Medicaid Whistleblower Reward False Claims Act Lawyer, Defense Contractor Fraud Whistleblower Reward Lawyer, Whistleblower Reward SEC Bounty Action Lawyer, and Whistleblower Reward CFTC Lawyer

Under Federal law, whistleblower recoveries can come through four different whistleblower recovery laws.  The Federal False Claims Act is the oldest of the laws and under this law the Federal Government has brought in approximately $30 Billion.  Under this law successful whistleblowers have been awarded over $3 Billion and these whistleblower rewards are expected to continue to expand as many states are enacting their own false claims act laws.  The Federal False Claims Act was recently amended by the Federal Enforcement and Recovery Act (FERA) including expanding the reach of the Federal False Claims Act to include subcontractors working under a government contractor and other parties working with government contractors.  The Federal False Claims Act was also expanded protection for employee whistleblowers.   States have also been encouraged through economic incentives to enact their own Medicaid False Claims Act whistleblower recovery laws.  These state whistleblower recovery laws must be at least as strong as the Federal False Claims Act whistleblower reward laws for the state to receive the increased economic benefits from the Federal Medicaid Fraud Recovery Program.

Another Federal whistleblower recovery law is IRS Tax Fraud Whistleblower Reward Program under section 406 of the Internal Revenue Code.  This whistleblower recovery law includes significant economic incentives and protections for whistleblowers to encourage people with specialized knowledge of significant tax fraud to step forward and report the fraud.  These protections if used properly can protect whistleblowers from retaliation and allow whistleblowers to recover large amounts of money for being the first to properly report significant tax fraud.  

Two relatively new whistleblower recovery laws are section 21F of the Securities Exchange Act (SEC Whistleblower Bounty Actions), and section 23 of the Commodity Exchange Act (CFTC Whisteblower Bounty Actions).  These laws were passed in the wake of Financial Market Melt Down in 2008 and in response to massive fraud in the financial markets.  These whistleblower recovery laws are designed to encourage people with specialized knowledge of significant investment fraud, securities fraud, SEC violations, commodity futures fraud, violations of the foreign corrupt practices act, and other financial fraud.  These whistleblower reward laws were designed to protect whistleblowers that step up and blow the whistle on financial fraud.

Importantly, the Foreign Corrupt Practices Act and the new SEC Whistleblower Incentive Program work together to reward whistleblowers with original and specialized knowledge and evidence of international business corporate bribery and illegal kickbacks.  These new international business whistleblower reward laws are part of a worldwide movement to expose and punish government corruption such as contract bribes, illegal kickbacks, and large scale international fraud.  These Foreign Corrupt Practices Act should help prevent government corruption in many countries including Russia, China, Mexico, and Brazil.

All of these whistleblower recovery laws have been recently passed or strengthened to provide additional protections and economic incentives to whistleblowers.  By contacting a whistleblower reward lawyer, a whistleblower can greatly increase their ability to make a recovery under these whistleblower recovery laws and use whistleblower protections to prevent or punish retaliation for reporting fraud.    

Medicaid Fraud Whistleblower Reward Lawsuit, Medicare Fraud Whistleblower Reward Lawsuit, Securities Fraud Whistleblower Reward Bounty Action Lawsuit, IRS Fraud Whistleblower Reward Lawsuit, Defense Contractor Fraud Whistleblower Reward Lawsuit, and other Whistleblower Reward Lawsuit Information   

For more information on whistleblower reward laws, please feel free to follow the above links in this post and/or the following link: Whistleblower Reward Laws.    

Mexican Oil Company PEMEX Will Probably Need Foreign Direct Investments to Stabilize Production, Resolve Environmental Issues, and Expand Deep Water Drilling Production by Texas Oil Company Foreign Corrupt Practices Bounty Action Lawyer, PEMEX Employee Confidential Whistleblower Reward Lawyer, and International Business Whistleblower Reward Lawyer Jason S. Coomer

Mexican Oil Company Employee Whistleblower Bounty Action Lawsuit, PEMEX Employee Confidential Whistleblower Reward Lawsuit, PEMEX Employee Bribe Bounty Action Lawsuit, Multinational Energy Company Government Official Bribe Bounty Action Lawsuit Information by Texas Oil Company Foreign Corrupt Practices Bounty Action Lawyer, PEMEX Employee Confidential Whistleblower Reward Lawyer, and International Business Whistleblower Reward Lawyer Jason S. Coomer

Mineral resources including oil and gas are owned by the Mexican government by constitutional law. Because of the government ownership of mineral interests, the energy sector including oil production and gas production is administered by the government with varying degrees of private investment. Mexico is the seventh-largest oil producer in the world. PEMEX is the public energy company that is in charge of administering research, exploration and sales of oil.  It is the largest company in Mexico, and the second largest company in Latin America after Brazil's Petrobras. 

Because of the Mexican tax system, PEMEX has limited resources to find new sources of oil or upgrade infrastructure.  It is estimated that the Mexican federal government takes over 90% of the national oil company PEMEX’s profits for the Mexican federal budget. For this reason PEMEX has been unable to maintain, upgrade, and/or expand its oil and gas production.  This failure to maintain and upgrade its oil and gas infrastructure has created declining production causing Mexico to slip from the sixth to the seventh largest producer of oil and gas.  It also has raised several environmental concerns with its onshore fields and pipelines as well as its plans to go into deep water drilling.  Though PEMEX claims most of its onshore problems are a result of vandalism, failure to properly invest in the Mexican petrochemical infrastructure is causing several issues.

To stabilize production output, the Mexican government and PEMEX are planning to move into deep water drilling to stabilized output after sharp decreases in some of it largest onshore aging fields.  It is estimated that there are about 30 billion barrels of oil beneath Mexico territorial Gulf waters, but the trick is to have sufficient investment capital to obtain deep water drilling technology.  By adopting new technology and investing in deep water drilling technologies, PEMEX hopes to have some 50 deepwater oil wells operating by 2015 and hopes this will stabilize production for many years.  It is yet to be see, what foreign investment will be needed to upgrade the PEMEX infrastructure to allow the necessary deep water production.

It should be interesting to see if PEMEX, like Brazil's Petrobras seeks foreign investment to obtain the capital needed to safely advance its plans for deep water offshore drilling.  If so, the competition for these oil infrastructure contracts could be fierce and include bribes of PEMEX officials, bribes of Mexican government officials, and other corrupt practices.  
 
Foreign Corrupt Practices Act Prohibits Bribes of Government Officials and Bounty Actions Allow Whistleblowers to Confidentially Report Violations Through Bounty Action Lawyers and Potentially Claim Large Rewards

The Foreign Corrupt Practices Act (FCPA) prohibits bribery of foreign officials by U.S. companies and foreign companies listed on the U.S. securities exchange.  The Foreign Corrupt Practices Act (FCPA) also requires such companies to maintain accurate books and records.  Foreign Corrupt Practices Act Whistleblowers that properly report violations of the Foreign Corrupt Practice Act by a U.S. or foreign companies listed on the U.S. securities exchanges can recover a large reward for exposing Foreign Corrupt Practices Act (FCPA) violations. 

The Mexican national oil company, PEMEX, has many of the same characteristics of  the Mexican electric company CFE.  CFE has been determined to be a foreign government instrumentality in the Lindsey Manufacturing case.  This means that PEMEX can probably be considered to be a foreign government instrumentality and will be covered under the FCPA and will be subject to Bounty Actions.  The characteristics of foreign government instrumentalities under the FCPA include whether the entity was created as a public entity; does its governing Board consist of high ranking government officials; does the entity describe itself as a government agency; does it perform a function that the Mexican government itself designates as a government function; and is the entity financed through governmental appropriations or through revenues obtained as a result of government-mandated taxes, licenses, fees or royalties.

For more information on the Mexican Economy, Foreign Direct Investments into the Mexican Economy, Mexican Government Official Bribe Bounty Actions, and Foreign Corrupt Practices Act Whistleblower Reward Lawsuits, please feel free to go to the following webpage: Mexico Contract Bribe FCPA Confidential Bounty Actions.

The Globlization of the Brazilian Economy has Brought Brazil Increased Foreign Investment, Economic Prosperity, and Government Corruption by International Foreign Corrupt Practices Act Lawyer Jason S. Coomer

Brazilian Government Official Bribe Lawsuit, Brazilian Government Official Illegal Kickback Lawsuit, & Brazil Foreign Corrupt Practices Bounty Action Information by US SEC Brazil Bribe Bounty Lawyer & Brazil Foreign Corrupt Practices Whistleblower Lawyer Jason S. Coomer

In 2011, Brazil became the sixth largest economy in the world.    One of the reasons for the growth of the Brazilian economy is that over the last several years the Brazilian government has put in place several policies to encourage foreign investment into Brazilian economy.  These policies have encouraged international commerce and increased Brazil's presence in the global economy.  Through these policies, the Brazilian economy has expanded rapidly with large amounts of foreign direct investments coming into the country.  Foreign companies are now moving into Brazil at a record pace, and many Brazilian companies are expanding internationally.  For foreign investors and large multinational corporations, the battle to invest into the Brazilian economy and potentially reap huge rewards has become extremely competitive.  This fierce competition combined with the Brazilian history of government corruption will be a test for many new anti-bribery and anti-corruption laws that have been passed around the world and are being considered in Brazil.

Foreign Corrupt Practices Act Prohibits Bribes of Government Officials and Bounty Actions Allow Whistleblowers to Confidentially Report Violations Through Bounty Action Lawyers and Potentially Claim Large Rewards

The Foreign Corrupt Practices Act (FCPA) prohibits bribery of foreign officials by U.S. companies and foreign companies listed on the U.S. securities exchange.  The Foreign Corrupt Practices Act (FCPA) also requires such companies to maintain accurate books and records.  Foreign Corrupt Practices Act Whistleblowers that properly report violations of the Foreign Corrupt Practice Act by a U.S. or foreign companies listed on the U.S. securities exchanges can recover a large reward for exposing Foreign Corrupt Practices Act (FCPA) violations. 

By combining the Foreign Corrupt Practices Act with the new SEC Whistleblower Incentive Program, whistleblowers with original and specialized knowledge and evidence of corporate bribery and illegal kickbacks are eligible to recover large economic awards.  By gathering this evidence and going through a lawyer, these whistleblowers can protect their identity through the process and potentially collect large rewards of 10% to 30% of the monetary sanctions including disgorged funds. 

Please keep in mind that the Foreign Corrupt Practices Act Bounty Action Whistleblower may be entitled to not only the amount of the illegal bribe or kickback, but the benefit of the illegal bribe or kickback.  As such, in cases where $50,000.00 bribe is made to obtain a $200 million building project such as a hospital or pipeline, the Foreign Corrupt Practices Act Bounty Action Whistleblower may be entitled to 10 to 30% of the $200,000,000.00 and the $50,000.00 translating into over a $20 million to $60 million award.

Brazilian Government Official Corruption, Brazilian Public Official Bribes, Brazilian Multinational Corporation Bribes, and Brazil Government Official Illegal Kickbacks Result in Political Action to Adopt Anti-Bribery Laws and Policies Similar to the US Foreign Corrupt Practices Act, UK Anti-Bribery Act, and other Global Trade Anti-Corruption Policies

With the rapidly expanding Brazilian economy, foreign direct investments into Brazil, and Brazilian companies expanding into other countries have come allegations of government official bribes, government agent kickbacks, fraud, embezzlement, and other forms of corruption. Included in these Brazilian government corruption scandals are several government officials that are being forced to resign, while other government officials in President Dilma Rousseff’s cabinet are under investigation for government corruption.  In the aftermath of these corruption scandals, the Brazilian Congress is in the process of enacting new law that would dramatically strengthen the Brazilian foreign bribery laws.  The foreign anti-bribery law is part of a global trend where governments around the world are cracking down on large corrupt multinational corporations that are offering bribes and kickbacks to government officials in order to obtain large government contracts, avoid health & safety regulations, bypass environmental laws, and exploit populations in foreign countries. 

It is thought that these Brazilian anti-bribery and anti-corruption reforms will improve Brazil's ability to attract legitimate foreign investment as well as improve Brazilian multinational corporations' ability to expand throughout South America, Latin America, and the world.  As Brazilian-based multinationals continue to expand internationally, they will want to ensure that they are protected from corrupt practices by other large multinational corporations and are given a fair chance to legally expand their businesses into international markets. 

Brazil Government Official Oil Contract Bribe Bounty Action Lawyer, Multinational Energy Company Brazil Contract Bribe Whistleblower Reward Lawyer, Brazilian Multinational Energy Corporation Bribe Lawyer, Oil Company Brazil Government Official Illegal Kickback Lawyer, Brazil Oil Lease Foreign Corrupt Practices Bounty Action Lawyer,  Brazil Oil Offshore Drilling Contract Bribe Whistleblower Reward Lawyer, & Oil Company Brazil Illegal Bribe Bounty Action Lawyer

A key Brazilian industry is the petrochemical industry.  With large natural reserves of oil and gas combined with foreign direct investments of technology, Brazil will soon pass China and the United Arab Emirates to become world's fifth largest oil producing nation, only behind Russia, Saudi Arabia, the USA and Iran.  Much of Brazil's oil and gas production comes from offshore drilling in deep water reserves.  Included in these deep water oil and gas reserves is the Santos Basin, which is located in the south Atlantic Ocean.  The Santos Basin is approximately 300 kilometers south east of Sao Paulo and is one of the world's largest oil prospects.  The Santos Basin is situated in deepwater and includes the large Tupi and Jupiter oil fields.  The Santos Basin also includes the Carioca/Sugar Loaf field which could contain as many as 40 billion barrels. 

The production of the Tupi and Jupiter fields combined with the development of production in the Sugar Loaf field should enable the Brazilian Oil Industry to bring in vast amounts of foreign capital into Brazil and allow Brazil to keep advancing its drilling technologies and developing its petrochemical infrastructure.  The rigs, platforms and tankers that will service and harvest Brazil's reserves in the coming years will probably be constructed using local suppliers, manpower and facilities instead of outsourcing to third party companies that do not feed directly into the local/national economy, however, deep technology and capital from around the world will be needed to develop the infrastructure and train the work force.  

The Brazilian energy industry is dominated by the Brazilian multinational energy company, Petrobras.  Petrobras is the forth largest company in the world measured by market capitalization.  It is also Brazil's semi-public oil company that is public and private hybrid.  As Brazil's public oil company, Petrobras has a goal of directing over 50% of its future oil and gas contracts to local Brazilian companies.  This protectionist economic policy is designed to help develop the Brazilian petrochemical industry and to limit the influence of foreign multinational oil companies on the Brazilian economy.  However, avoiding corruption including Santos Basin lease bribes, Petrobras employee bribes, Brazilian government official bribes, Petrobras oil lease bribes, and other potential Petrobras corruption may prove difficult as the historical culture of Brazilian business and Brazilian government includes substantial corruption.

Petrobras has pledged a $224 billon investment in the Santos Basin through 2014 which should be able to bring in advanced technology and industry from large foreign multinational energy companies.  This large amount of investment capital combined with the vast rich Brazilian oil and gas reserves, will bring in fierce competition for these large Brazilian contracts, Brazilian offshore drilling leases, and Brazilian leases.  This fierce competition over these huge riches will definitely test the Brazilian government as to if corrupt practices will continue to be common in Brazil or will new anti-bribery laws, whistleblowers, informants, honest Petrobras employees, honest government officials, and honest Petrobras officers be able to manage these resources for the good of the Brazilian economy and Brazilian people?

Brazilian Oil Company Employee Confidential Whistleblower Lawyers, Brazilian Energy Company Illegal Kickback Bounty Action Lawyers, Petrobras Employee Protected Whistleblower Bounty Action Lawyers, Petrobras Energy Company Employee Confidential Whistleblower Lawyers,  and Multinational Oil Company Violations of the Foreign Corrupt Practices Act Whistleblower Lawyers and Anonymous Multinational Oil Company Whistleblower Lawyers

Corrupt Foreign Multinational Oil Companies, Multinational Construction Companies, and Multinational Energy Companies that pay illegal kickbacks and bribes to Brazilian government officials and former Brazilian government officials in exchange for Brazilian drilling contracts, Brazilian pipeline contracts, Brazilian oil leases, Brazilian offshore drilling contracts, Brazilian infrastructure contracts, and other Brazilian large building projects can be brought to justice and made to pay large penalties under the Foreign Corrupt Practices Act.  The whistleblowers that bring these corporations to justice may be able to collect large economic rewards under the  Securities Exchange Act (SEC Whistleblower Bounty Actions) and the Commodity Exchange Act (CFTC Whisteblower Bounty Actions).

For more information on  Brazilian Bribe Confidential Whistleblower Bounty Actions, Brazilian Corrupt Government Official Anonymous Whistleblower Bounty Actions, Brazil Government Agent Whistleblower Reward Lawsuits, Multinational Energy Company Contract Bribe Whistleblower Bounty Actions and discussion of the Brazilian Economy and Brazilian Government Corruption, please go to the following webpage: Brazilian Government Official Bribe Lawsuit, Brazilian Government Official Illegal Kickback Lawsuit, Brazil Foreign Corrupt Practices Bounty Action Lawsuit, Brazil Bribe Confidential Whistleblower Reward Lawsuit, Multinational Oil Company Bribe Lawsuit, & Brazil Illegal Bribe Bounty Action Lawsuit Information